Identification | Back Directory | [Name]
CSF1R-IN-1 | [CAS]
2095849-04-8 | [Synonyms]
CSF1R-IN-1 CSF1R-IN-22 3-Pyridinecarboxamide, 5-(1-methyl-1H-pyrazol-4-yl)-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]- | [Molecular Formula]
C25H20F3N5O2 | [MDL Number]
MFCD31813597 | [MOL File]
2095849-04-8.mol | [Molecular Weight]
479.45 |
Chemical Properties | Back Directory | [Boiling point ]
528.3±50.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
11.58±0.70(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Uses]
CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM. | [in vivo]
CSF1R-IN-1 has favorable pharmacokinetics when dosed orally to mice. It appears suitable for in vivo pharmacology testing in the appropriate preclinical tumor model to demonstrate proof of concept.[1]. Animal Model: | Male CD-1 mice, 25-35 grams (8-11 weeks old)[1] | Dosage: | 2 mg/kg IV or 10 mg/kg orally (Per Os) | Administration: | i.v. or oral | Result: | I.V.: Cmax=3.55, T1/2=0.87
P.O.: Cmax=4.6, T1/2=1.8, Bioavailability=64%
|
| [References]
[1] Ramachandran SA, et al. Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors. Bioorg Med Chem Lett. 2017 May 15;27(10):2153-2160. DOI:10.1016/j.bmcl.2017.03.064 |
|
Company Name: |
InvivoChem
|
Tel: |
13549236410 |
Website: |
https://www.invivochem.cn/ |
|